Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change to Date of Q2 Interim Report

Ayima today announces that it will change the date of the release of the Q2 Interim report, currently scheduled for August 19, 2021.  The new date for the release will be August 12, 2021. The reason for the change is improved accounting procedures have meant that the report will be completed sooner than previously expected. In light of these improved procedures, Ayima will also re-assess the scheduled dates for the release of subsequent reports and notify the market when the new dates have been decided.

Outokumpu – Manager transaction: Kari Jordan

Outokumpu OyjStock exchange releaseManager transactionAugust 9, 2021 at 12.00 noon EESTOutokumpu – Manager transaction: Kari Jordan Outokumpu has received a notification from Kari Jordan, member of the Board of Directors, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation. Detailed information about the transaction is given in the table below. Name of the manager Kari JordanPosition in the issuer Member of the Board of DirectorsIssuer Outokumpu OyjIssuer’s LEI reference 5493009YRUJJDCFF0R80

Notification of a change in holdings under chapter 9, section 10 of the Finnish Securities Market act

STOCKMANN plc, Major shareholders announcements 9.8.2021 at 10:30 EET Stockmann has been notified that Denali European Opportunities Designated Activities Company’s holding in Stockmann plc’s shares and voting rights has increased above 10 per cent in connection with a purchase of shares on 5 August 2021. 1. Name of the target company: Stockmann plc 2. Date of the change in holdings: 5.8.2021 3. Shareholder’s position according to the notification: Number Percentage Target company’s total of of the

Results from Groundbreaking Study with Prostatype® Additionally Strengthens the Clinical Benefits

Prostatype Genomics continues to deliver on the overall strategy of the Company and the previously communicated milestones. One of two main focus areas is the continued strengthening of the scientific footprint through scientific studies performed by internationally recognized clinics and research institutions. An additional milestone in the development of the Company has now been achieved through the groundbreaking clinical study with Prostatype® that has been performed at the Uppsala University Hospital (“Akademiska”), under the leadership of associate professor Michael Häggman at the

Hemnet on the housing market in July

·Increasing number of buyers expect falling property prices ·Unusually high influx of homes for sale in July ·Record activity on the house market for a month of July   The housing market in July was unusually active for a summer month. More houses were both listed and sold than in any previous month of July for as long as Hemnet has had a continuous data. Activity in the apartment market was also high compared to the usual July pattern, albeit slightly lower than in July 2020.In Hemnet’s Buyers’ Barometer, price expectations fell for the third month in a row. The

The exercise period for warrants of series TO1 begins today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.Today, on August 9, 2021, the subscription period begins for the warrants of series TO1 in Pharmacolog i Uppsala AB (publ) (“Pharmacolog” or the “Company”) that were issued during the

BEWI ASA announces intention to issue new unsecured floating rate sustainability-linked bonds

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933), AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Subject to BEWiSynbra Group AB (publ) (a wholly owned subsidiary of BEWI ASA) (“BEWiSynbra”) obtaining approval

BEWI initiates written procedures relating to secured bonds due 2022 and 2023 and announces intention to issue new unsecured sustainability-linked bonds

BEWI initiates written procedures relating to secured bonds due 2022 and 2023 and announces intention to issue new unsecured sustainability-linked bonds NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933), AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR

poLight ASA – follow-up purchase order for barcode scan engine product

Horten, 9 august 2021 - poLight ASA (OSE: PLT) today announced that the company has received a purchase order for TLens of approximately NOK 1,450,000. The purchase order is related to the barcode scan engine product already released to the market. The purchase order is expected to be delivered within end of Q1-2022. “This customer forms an important basis for us in the barcode segment. We expect to grow our customer base in this area in the future“, said Dr. Øyvind Isaksen, the CEO of poLight.

Zalaris UK awarded Most Outstanding Payroll and HR Solutions Provider of the Year 2021

Zalaris ASA, a leading provider of Outsourced Payroll and HR services, is happy to announce it has been recognised as the winner of “The Most Outstanding Payroll and HR Solutions Provider of the Year 2021”.Awarded by CEO Monthly magazine as part of their 2021 Business Elite Awards. Read more about the awards here . The award recognises Zalaris’ cost-effective payroll solution which simplifies complex HR & Payroll processes with the ability to seamlessly integrate with all major HRIS systems and other third-party solution, whilst ensuring

New real-world driving tests with Triboron show significant reduction of fuel consumption and CO\2\ emissions

Triboron International AB (publ) (”Triboron"), in collaboration with the leading UK testing company Emissions Analytics, has conducted Real Driving Emissions (”RDE”) tests that show significant reduction in both fuel consumption and CO\2\ emissions.Euro 6 standardsWhen the Euro 6 standard was introduced in the EU in September 2015, cars were tested for emissions in a laboratory. These tests that were known to be unrealistic when compared with real-world driving and cars could also be optimized to perform particularly well in laboratory settings. To ensure even cleaner cars, the EU

Diamyd Medical secures precision medicine patent for prevention and treatment of autoimmune diabetes

The European Patent Office has informed Diamyd Medical that the Company’s patent application regarding prevention and treatment of autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene will be granted. The patent is valid until 2035 and provides central protection in Europe for the treatment or prevention of genetically defined autoimumune diabetes using GAD, which is the active component in the therapeutic diabetes vaccine Diamyd[®]. The patent claims cover the patient population in which Diamyd[®] has shown efficacy and is targeted in the upcoming Phase III trial DIAGNODE-3.“

Invitation to presentation of Balco’s second quarter report 2021

Balco’s interim report for the second quarter 2021 will be published at 07:30 CET on August 18, 2021. A web-cast telephone conference will be held at 09:00 CET the same day, where CEO and President Kenneth Lundahl and CFO Michael Grindborn will present the results for the second quarter 2021.A possibility will be given to ask questions via the webcast and follow the presentation material live. The webcast, which afterwards also will be available on demand, will be accessible at Balco’s financial website, www.balcogroup.se or via the following link: https://tv.streamfabriken.com/balco-q2-

Forxiga approved in the EU for CKD

09 August 2021 07:05 BST Forxiga approved in the EU for the treatment of chronic kidney disease in patients with and without type-2 diabetes Approval based on unprecedented DAPA-CKD Phase III data is the most significant advancement in chronic kidney disease in more than 20 years AstraZeneca's Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The approval by the European Commission is based on positive results

2020 Bulkers Ltd. (2020) – Invitation to webcast and conference call Q2 2021 results

2020 Bulkers Ltd. will release its financial results for the second quarter of 2021 on Wednesday, August 11, 2021. A conference call and webcast will be held at 3:00 PM CET. The earnings report and presentation will be available from the Investor Relations section on www.2020bulkers.com on the same day. In order to listen to the presentation, you may do one of the following: Listen-only webcast (including the slide presentation): https://edge.media-server.com/mmc/p/9cv4wvv4 or you can click the “Webcast” link on www.2020bulkers.com/investor-relations/ Conference Call: Dial in

Panoro Energy – Block G Equatorial Guinea update

Oslo, 9 August 2021 – Panoro Energy ASA (“Panoro”) notes the operations update issued today by joint venture partner Kosmos Energy in relation to the producing Block G (Ceiba field and Okume Complex), offshore Equatorial Guinea, where Panoro holds a 14.25% Working Interest. Gross production at Block G averaged 29,100 bopd in the second quarter. The Okume upgrade project is expected to be completed in the fourth quarter and will contribute additional power, water injection and gas lift capacity necessary for further de-bottlenecking of the facilities and additional electrical

Graphene binds drugs which kill bacteria on implants

Bacterial infections relating to medical implants place a huge burden on healthcare and cause great suffering to patients worldwide. Now, researchers at Chalmers University of Technology, Sweden, have developed a new method to prevent such infections, by covering a graphene-based material with bactericidal molecules. “Through our research, we have succeeded in binding water-insoluble antibacterial molecules to the graphene, and having the molecules release in a controlled, continuous manner from the material” says Santosh Pandit, researcher at the Department of Biology and

Flexion Mobile signs Top-tier title Evony The King's Return

Currently the highest grossing Google Play title in Flexion's growing portfolioLONDON, 9th of August, 2021 – Flexion Mobile Plc (Nasdaq: FLEXM), the Android games distribution company today announced that it has signed a distribution agreement with Top Games Inc for their top grossing game Evony the King's Return, the hot real-time strategy MMO of 2021. Flexion will distribute the game in all its channels including Amazon, Samsung, Huawei, and ONEstore. According to Sensor Tower, the game generated approx. USD 8 million to the developer in Google Play in July. This makes it Flexion's

Invitation to half year 2021 business review briefing

Remedy Entertainment Plc | Press release 9:00 pm (EEST) 9 August 2021 Invitation to half year 2021 business review briefing Remedy will publish its business review of April–June 2021 on Friday 13 August 2021 at 09:00 am (EEST) at https://investors.remedygames.com/announcements-and-releases/ The company will host an English language briefing webcast and conference call on the same day at 11:00 am (EEST). Remedy’s business review will be presented by CEO Tero Virtala and CFO Terhi Kauppi. The presentation will be followed by a Q&A session for investors, analysts, and media.

Quickbit selects Worldpay from FIS for merchant acquiring services

Quickbit has entered into an agreement with Worldpay from FIS to provide global merchant acquiring and related services for card-to-crypto purchases. Worldpay is a leading provider of payment processing solutions with extensive experience and knowledge of cryptocurrencies.Worldpay is part of Fidelity National Information Services, Inc. (NYSE:FIS), a leading provider of technology solutions for merchants, banks and capital markets firms globally. For more information about FIS, please go to https://www.fisglobal.com/en/about-us “We are particularly pleased to be partnering with a leading

Calliditas Receives FDA Fast Track Designation for setanaxib in PBC

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for its lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US and Europe.The FDA Fast Track program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions and that demonstrate

Enhertu head-to-head trial meets primary endpoint

9 August 2021 07:00 BST Enhertu significantly improved progression-free survival in DESTINY-Breast03head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer IDMC recommended unblinding based on primary efficacy endpoint demonstrating superiority; results also indicate strong trend toward improved overall survival Plans for global regulatory submissions underway Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo

There are no items matching the current filter
There are no more items matching the current filter
Back to top